Vir(VIR) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities – Positive preliminary Phase 2 chronic hepatitis delta study data presented at EASL™ Congress 2024, FDA IND clearance with Fast Track Designation received underscoring the potential of combination therapy – – Exclusive license agreement with Sanofi bolsters clinical pipeline – – Strategic workforce restructuring and phasing out of influenza, C ...